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Abstract
Rationale: Genetic polymorphisms in the asthma susceptibility gene, urokinase
plasminogen activator receptor (uPAR/PLAUR) have been associated with lung
function decline and uPAR blood levels in asthma subjects. Preliminary studies
have identified uPAR elevation in asthma; however, a definitive study regarding
which clinical features of asthma uPAR may be driving is currently lacking.
Objectives: We aimed to comprehensively determine the uPAR expression profile
in asthma and control subjects utilizing bronchial biopsies and serum, and to
relate uPAR expression to asthma clinical features.
Methods: uPAR levels were determined in control (n = 9) and asthmatic (n = 27)
bronchial biopsies using immunohistochemistry, with a semi-quantitative score
defining intensity in multiple cell types. Soluble-cleaved (sc) uPAR levels were
determined in serum through ELISA in UK (cases n = 129; controls n = 39) and
Dutch (cases n = 514; controls n = 96) cohorts.
Measurements and main results: In bronchial tissue, uPAR was elevated in
inflammatory cells in the lamina propria (P = 0.0019), bronchial epithelial
(P = 0.0002) and airway smooth muscle cells (P = 0.0352) of patients with
asthma, with uPAR levels correlated between the cell types. No correlation
with disease severity or asthma clinical features was identified. scuPAR serum
levels were elevated in patients with asthma (1.5-fold; P = 0.0008), and we
identified an association between high uPAR serum levels and severe,
nonatopic disease.
Conclusions: This study provides novel data that elevated airway and blood
uPAR is a feature of asthma and that blood uPAR is particularly related to sev-
ere, nonatopic asthma. The findings warrant further investigation and may pro-
vide a therapeutic opportunity for this refractory population.
Asthma, a chronic inflammatory airway disorder, is known to
cause widespread variable airflow obstruction that is often
reversible, spontaneously or with treatment, and presents with
airway hyperresponsiveness (1). The urokinase plasminogen
activator receptor (uPAR) is a glycosylphosphatidylinositol
(GPI)-anchored membrane protein (2–4) translated from the
gene PLAUR (4). uPAR has been associated with asthma at
the biological and cellular level (5–8), with elevated uPAR
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levels identified in asthma patient induced sputum (9) and
bronchial epithelium (8). uPAR is a serine protease receptor
and is involved in the generation of plasmin with subsequent
proteolytic effects on a range of substrates; however, uPAR
also has plasmin-independent functions, for example migra-
tion and proliferation, by interacting with a wide range of pro-
teins (10). A soluble-cleaved form of the receptor (scuPAR),
arising from lipolytic cleavage of the GPI anchor by factors
including phospholipase D (11), also exists. scuPAR is struc-
turally identical to the membrane-bound receptor but is able
to interact with a number of cell factors, for example integrins
and G protein-coupled receptors. scuPAR is thought to have
functions beyond acting as a decoy receptor for the main
uPAR ligands, for example uPA (12).
In a population of adult individuals, we demonstrated that
higher circulating (serum) scuPAR levels were associated with
asthma prevalence in 514 affected individuals when compared
to 104 controls (13), suggesting a relationship between
asthma and the circulating receptor. This is supported by our
earlier family-based genetic association study, determining
that PLAUR is an asthma susceptibility gene, where poly-
morphisms were associated with asthma, lung function, lung
function decline and bronchial hyperresponsiveness in
patients with asthma (7). These same PLAUR polymor-
phisms were also found to be associated with higher scuPAR
levels circulating in serum in children with asthma. This sug-
gests a link between circulating scuPAR expression and
degree of asthmatic lung function, providing insight into the
possible process by which scuPAR is associated with asthma.
Asthma is classified as a disease with an allergic compo-
nent, with allergic asthma being a recognized endotype of the
disease (14). Asthma can be defined as either atopic with trig-
gering mechanisms involving allergens originating from, for
example pollen, or nonatopic, which is not directly triggered
by any known allergen, but potentially through the activation
of innate receptors such as those for interleukin-33 (IL-33)
and the granulocyte macrophage colony-stimulating factor
(GM-CSF) (15, 16). Nonatopic asthma also generally mani-
fests later in life and is often more severe than atopic asthma
(17). Several approaches have been used to identify asthma
endotypes including cluster analyses that confirm distinct
atopic and nonatopic clusters (18–20).
In this study, we investigated uPAR expression profiles in
lung biopsies and peripheral (serum) compartments of
asthma subjects. We set out to confirm and extend previous
observations carried out in a bronchial epithelial cell model
(8) and serum in asthma (13), utilizing several cohorts for
serum analyses and ex vivo bronchial biopsies. We aimed to
build upon previous observations made in cell-culture models
and at the genetic level by identifying whether expression in
bronchial biopsies and serum are related to asthma clinical
phenotypes such as lung function and allergy (atopy). We
provide in-depth analysis of uPAR expression in various air-
way structural cells and in serum, further defining the rela-
tionship between uPAR expression and clinical features of
asthma.
Materials and methods
Cohort characteristics
UK biopsy cohort
Asthmatic subjects with a history and objective evidence of
asthma (21), and nonasthmatic controls were recruited from
Leicester, UK. Asthma severity was defined by Global Initia-
tive for Asthma criteria (21). Subjects underwent extensive
clinical characterization including allergen skin prick tests,
spirometry, methacholine bronchial challenge (PC20), sputum
induction and video-assisted fiber optic bronchoscopic exami-
nation (Table S1). The study was approved by the Leicester-
shire Ethics Committees, and all patients gave their written
informed consent.
Cohorts for serum analyses
Dutch cohort. Asthma (n = 514) and spouse control (n = 96)
subjects were ascertained through an asthmatic proband and
characterized using a standardized study protocol as
described (13, 22). Ethical approval was obtained from the
University Medical Center, Groningen Medical Ethics Com-
mittee (MEC 96/04/077 and MEC 90/09/178). Subject-based
atopy was determined using the PhadiatopTM test (Phadia
AB, Uppsala, Sweden), a commercially available variant of
serum-specific IgE assay (23). Demographics of the Dutch
cohort are shown in Table S2.
UK cohort. A cohort of 168 Caucasian individuals were
recruited from the Southampton area based on an asthmatic
proband (n = 129) or no history of asthma or allergic disease
for the controls (n = 39) (24, 25). All individuals were
between the ages of 17 and 75. Asthma severity was classified
by the BTS/SIGN guidelines (26). Demographics of the UK
cohort are shown in Table S3.
Immunohistochemistry (IHC) in lung biopsies from patients
with asthma
Sections from control and asthmatic glycomethacrylate-
embedded bronchial biopsies were stained using an anti-
uPAR antibody (sc-32764; Santa Cruz Biotechnology Santa
Cruz, California, United States) or an anti-mouse IgG iso-
type control (M7894; Sigma Gillingham, Dorset, United
Kingdom). A semi-quantitative score defined epithelial
expression intensity (0 = none, 1 = low, 2 = moderate,
3 = high); mean of two sections per donor, scored by a
blinded observer.
Analysis of soluble protein levels
scuPAR human serum levels were determined using a Duo-
set ELISA (R&D systems, Abingdon, Oxfordshire, UK).
All samples were diluted 1 : 8 in 1% bovine serum albumin
in phosphate-buffered saline.
© 2016 The Authors. Allergy Published by John Wiley & Sons Ltd
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Statistical analyses
Statistical analyses were carried out using SPSS (PASW) ver-
sion 16.0 (IBM, North Harbour, Portsmouth, Hampshire,
UK) and GRAPHPAD PRISM version 5.03 (GraphPad Software
Inc., La Jolla, California, United States). Correlation analyses
were carried out on continuous variables using Spearman’s
correlation. Associations involving discrete variables and/or
confounders for scuPAR level analyses were systematically
investigated in the regression model. Previously determined
confounders for scuPAR levels in serum including age in years
(at time of sampling), height (in metres at time of sampling),
weight (in kilograms at time of sampling) and smoking pack/
year value were shown to have a statistically significant effect
on scuPAR levels and were included in the final regression
model as has been described previously (13). As there was a
priori evidence of a relationship between the levels of scuPAR
in serum and asthma diagnosis, we considered P < 0.05 signifi-
cant for these analyses. In the correlation analyses, the out-
come variables are not independent (e.g. FEV1 and FEV1/
FVC), and therefore, we did not apply correction for multiple
testing based on the number of tests, for example Bonferroni
correction, as this would be over conservative. To provide con-
fidence in the findings and to mitigate Type I and Type II
error, we sought independent replication of findings in multi-
ple cohorts. We therefore report P-values of <0.00005–0.05.
Results
uPAR is elevated in multiple airway cell types in patients
with asthma
Immunohistochemical analyses of bronchial biopsies from
patients with asthma (n = 27) and nonasthmatic controls
i
ii
A
A
B
B
C
Figure 1 (i) Expression of uPAR in bronchial biopsies. (A) healthy
control, (B) asthma subject revealing staining in the epithelium and
cells within the lamina propria (highlighted by arrows) and (C)
asthma subject revealing staining in the epithelium and airway
smooth muscle (9400). Images are representative of a larger data
set of lung biopsy slides. (ii) Median levels of uPAR are elevated in
asthmatic subjects when compared to nondisease controls.
Investigating the median expression levels of uPAR as defined
through immunohistochemistry per number of cells within bronchial
biopsies has identified an increased expression in asthma biopsies
when compared to controls (A; uPAR + cells in lamina propria med-
ian uPAR: P = 0.0019). When classified into a semi-quantitative
score, staining identified that this elevation of uPAR levels occurred
in smooth muscle cells (B; P = 0.0352). *p<0.05;**p<0.01
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(n = 9) identified uPAR expression localized to inflammatory
cells present in the lamina propria, within the cytoplasm of
the epithelium and in smooth muscle cells (Fig. 1i). Expres-
sion data were grouped into a semi-quantitative score of
0 = none, 1 = low, 2 = moderate or 3 = high, as previously
outlined (8). Utilizing this scoring system, we identified
that uPAR expression was elevated in layers of the airway
wall including the lamina propria and smooth muscle band-
ing in asthmatic subjects, when compared to corresponding
controls [smooth muscle cells: median 0.5 vs 0.0; 95% CI:
0.0–1.0 vs 0.0–0.0; P = 0.0352; uPAR + cells in lamina pro-
pria: median 5.536 vs 0.000; 95% CI: 3.73–10.64 vs 0.0–
4.15; P = 0.0019 (Fig. 1ii). As previously reported, uPAR
levels in the asthma epithelium were also elevated (8)].
Analyses identified clear correlations between the popula-
tions of cells staining positive for uPAR, that is if uPAR
was elevated in one cell type, it was accompanied by
increased staining across the tissue in the other cell types
(correlation coefficient 0.2; P < 0.05) (Table 1). However,
no significant association was identified between total
uPAR levels and other clinical features of asthma including
lung function and atopic status (Table 1).
Elevation of serum-soluble-cleaved uPAR is a feature of
asthma
To replicate our previous observation showing elevation of
serum scuPAR in asthma subjects when compared to nondis-
eased controls (13), we utilized asthma (n = 129) and control
subject (n = 39) sera from an independent UK cohort not
previously used in our studies. These analyses confirmed ele-
vation of serum scuPAR in asthmatic individuals (median
scuPAR = 3056 pg/ml; 95% CI: 2706–3377) when compared
to unrelated nonrespiratory disease controls (median
scuPAR = 1987 pg/ml; 95% CI: 1442–2836; P = 0.0002)
(Fig. 2A). Stratification in this cohort, based on severity as
defined by the BTS/SIGN guidelines, identified that elevated
serum scuPAR in asthma were primarily driven by the severe
asthma subjects (BTS/SIGN ≥ 3) (Fig. 2B). Here, serum scu-
PAR was elevated in severe asthma (n = 93; median
scuPAR = 3271 pg/ml; 95% CI: 2841–3568) when compared
to moderate asthma (n = 36; median scuPAR = 2233 pg/ml;
95% CI: 1724–2838; P < 0.01) and controls with no history of
asthma or allergic disease (n = 39; median scuPAR = 1987 pg/
ml; 95% CI: 1442–2836; P < 0.0001) (Fig. 2B). No statistically
significant difference was noted between controls and moder-
ate asthma subjects (Fig. 2B).
Elevation of serum scuPAR levels is driven by a nonatopic
phenotype
To investigate whether lung uPAR expression and/or circu-
lating serum scuPAR are associated with allergic asthma, we
carried out a logistic regression in the lung biopsy data set,
the Dutch serum cohort that originally identified elevated
scuPAR in asthma (13) and the UK serum data set based on
atopic status. While no association could be identified for
lung uPAR levels and atopic status (Table 1), serum scuPAR
was elevated in nonatopic asthma (n = 188; median
scuPAR = 4219 pg/ml; 95% CI: 3913–4525) when compared
to the atopic asthma population using all subjects from the
UK and Dutch cohorts (n = 382; median scuPAR = 3600 pg/
ml; 95% CI: 3380–3818; P < 0.0001). Importantly, differen-
tial expression based on atopic status was observed indepen-
dently in both cohorts (Fig. 3).
Table 1 Correlation and logistic regression analyses between
uPAR levels and asthma clinical phenotypes in the bronchial
biopsies
Phenotype Number OR/r2 P-value
95%
CI for OR
(A) Epithelial expression in patients with asthma
Age 27 0.002 0.820 n/a
Sex 27 0.003 0.769 n/a
Smoking pack years 12 0.030 0.593 n/a
GINA 27 0.954 0.945 0.249–3.659
Atopy 27 3.065 0.207 0.538–17.462
Baseline FEV1
(%Pred)
27 0.021 0.475 n/a
Baseline FEV1/FVC 27 0.005 0.729 n/a
uPAR + cells/mm2
(lamina propria)
27 0.208 0.017 n/a
SQS ASM 27 0.225 0.019 n/a
(B) ASM expression in patients with asthma
Age 24 0.024 0.468 n/a
Sex 24 0.011 0.617 n/a
Smoking pack years 11 0.119 0.285 n/a
GINA 24 3.994 0.059 0.837–14.284
Atopy 24 1.222 0.775 0.309–4.840
Baseline FEV1
(%Pred)
24 0.121 0.096 n/a
Baseline FEV1/FVC 24 0.029 0.426 n/a
uPAR + cells/mm2
(lamina propria)
24 0.121 0.096 n/a
SQS EPI 24 0.207 0.025 n/a
(C) uPAR + cells/mm2 in the lamina propria in patients with asthma
Age 27 0.065 0.200 n/a
Sex 27 0.002 0.814 n/a
Smoking pack years 12 0.027 0.612 n/a
GINA 27 0.997 0.939 0.928–1.072
Atopy 27 1.084 0.123 0.978–1.202
Baseline FEV1
(%Pred)
27 0.023 0.449 n/a
Baseline FEV1/FVC 27 0.032 0.372 n/a
SQS EPI 27 0.208 0.017 n/a
SQS ASM 24 0.154 0.058 n/a
SQS, semi-quantitative score; EPI, epithelial cells; ASM, airway
smooth muscle cells.
Spearman’s correlation analyses on linear data points and logistic
regression on binary values identifies a strong correlation between
cellular uPAR expression between different airway cells and no
association with clinical phenotypes. GINA was categorized into
mild–moderate (GINA1–3) vs severe (GINA 4, 5) disease due to lim-
ited numbers. 95% Confidence intervals are presented for the odds
ratio values.
Bold text identifies statistically significant correlations; P<0.05.
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Serum scuPAR levels are correlated to atopy and airway
obstruction
To evaluate the correlation between scuPAR circulating
levels and clinical measures in asthma, we carried out Spear-
man’s correlation and logistic regression analyses on the UK
and Dutch cohorts and the combined data set as appropriate
(Table 2). We identified that circulating scuPAR levels were
associated with atopic status in individual and combined
cohorts using this approach (combined: OR = 1.0002;
P = 0.000068) (Table 2C). In both UK and Dutch cohorts,
serum levels were also positively correlated with FEV1/FVC
ratio (combined cohort: r2 = 0.008; P = 0.035) (Table 2C).
Other correlations with age (Dutch: r2 = 0.015; P = 0.002)
(Table 2A), smoking pack/years (UK: r2 = 0.054; P = 0.009)
and percentage predicted FEV1 (UK: r
2 = 0.048; P = 0.013)
(Table 2B) as well as association with steroid use (Yes/No)
(Dutch: OR = 1.0002; P = 0.009) (Table 2A) were identified
but did not replicate between cohorts.
Quartile analysis confirms that serum scuPAR levels are
associated with atopic status
To identify whether a subpopulation drives clinical pheno-
type associations for serum scuPAR, we carried out a quar-
tile analysis based on uPAR serum levels within our cohorts,
separately and combined. In the Dutch data set, we identified
an association with bronchodilator response measured using
percentage change in FEV1 (pre/post-BD) (mean uPAR quar-
tile values; 19.30% > 18.99% > 16.70% > 14.80% (%
change in FEV1); P = 0.011). There was also an increase in
the pre- (0.65 < 0.68 < 0.69 < 0.70; P = 0.005) and
Figure 2 Elevations of serum scuPAR levels in asthma are dri-
ven by severity status in the UK cohort. (A) Measurement of
serum levels of scuPAR in 129 individuals with asthma and 39
individuals with no respiratory disease from the UK cohort
demonstrated that serum levels of scuPAR are elevated in
asthma. (B) When stratified according to asthma severity as
defined by the guidelines set out by BTS, we identify that
serum scuPAR is elevated in severe asthmatics when compared
to both moderate asthmatics and nonrespiratory diseased con-
trols .**p<0.01; ***p<0.001
Figure 3 Serum scuPAR levels are associated with atopic status in
asthma in the Dutch (A) and UK (B) data sets. Stratification of the
asthmatic population according to atopic status in the UK or Dutch
data sets identifies an elevated level of uPAR in nonatopic asthma
*p<0.05; ***p<0.001.
© 2016 The Authors. Allergy Published by John Wiley & Sons Ltd
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postbronchodilator (0.71 < 0.74 < 0.75 < 0.76; P = 0.003)
FEV1/FVC ratio across uPAR quartiles. These associations
were not replicated in the UK or combined data sets
(Table 3). A significant negative correlation between atopic
status and the scuPAR quartiles was also observed indepen-
dently and in the combined cohorts (combined nonatopic
(%) across quartiles: 17.5 > 25.3 >36.0 > 38.1; P < 0.0001,
Table 3).
Table 2 Correlation and logistic regression analyses between scuPAR levels in the individual UK and Dutch cohorts and combined cohorts
with asthma clinical phenotypes
Phenotype Number OR/r2 OR 95% CI P-value
(A) Soluble uPAR in serum – Dutch Asthma Cohort
Age 514 0.0262 n/a 0.00023
Sex 514 0.0029 n/a 0.222
Smoking pack years 320 0.0001 n/a 0.831
Atopy 441 1.0002 1.000115–1.000306 0.000016
Baseline FEV1 (%Pred) 510 0.0045 n/a 0.132
Baseline FEV1/FVC 514 0.0132 n/a 0.009
FEV1 reversibility (%) 514 0.0050 n/a 0.106
Steroid use 427 1.0002 1.000077–1.000377 0.009
(B) Soluble uPAR in serum – UK Asthma Cohort
Age 125 0.0213 n/a 0.104
Sex 125 0.0361 n/a 0.340
Smoking pack years 53 0.1875 n/a 0.001
Atopy 118 1.0004 1.000043–1.000741 0.028
Baseline FEV1 (%Pred) 129 0.0479 n/a 0.013
Baseline FEV1/FVC 129 0.0533 n/a 0.008
FEV1 reversibility (%) 129 0.0199 n/a 0.111
Steroid use 76 1.000184 1.000000–1.000587 0.283
(C) Soluble uPAR in serum – Combined Asthma Cohort
Age 639 0.015 n/a 0.002
Sex 639 0.004 n/a 0.593
Smoking pack years 373 0.002 n/a 0.389
Atopy 559 1.0002 1.000089–1.000262 0.000068
Baseline FEV1 (%Pred) 643 0.004 n/a 0.104
Baseline FEV1/FVC 643 0.0083 n/a 0.035
FEV1 reversibility (%) 643 0.001 n/a 0.333
Steroid use 503 1.000217 1.000164–1.000398 0.001
OR, Odds ratio for logistic regression.
Correlation analyses using linear regression identified a positive relationship between the circulating uPAR and FEV1/FVC ratio independently
in both cohorts. Logistic regression identified a similar relationship between uPAR and atopic status in both cohorts and steroid use (Yes/
No) in the combined and Dutch cohorts only. 95% Confidence intervals are presented for the odds ratio values.
Bold text identifies statistically significant correlations; P<0.05
Table 3 Interquartile analyses of the UK and Dutch cohorts (P-values)
UK Dutch Combined
Reversibility (change FEV1) 0.394 0.011 (19.30% > 18.99% >
16.70% > 14.80%)
0.317
Baseline FEV1 0.208 0.061 0.428
Post-BD FEV1 n/a 0.256 n/a
Baseline FEV1/FVC 0.188 0.005 (0.65 < 0.68 < 0.69 < 0.70) n/a
PostBronchodilator FEV1/FVC 0.188 0.003 (0.71 < 0.74 < 0.75 < 0.76) 0.258
Atopy 0.044 (38.9% > 51.4%
> 70.0% < 61.1%)
<0.001 (11.0% > 18.0% >
25.2% > 35.2%)
0.001 (17.5% > 25.3% >
36.0% > 38.1%)
BD, bronchodilator.
Analysis identifies an association with atopic status across both cohorts with some evidence for association with lung function and
reversibility (change in FEV1 postbronchodilator) in the Dutch cohort.
Bold text identifies statistically significant correlations; P<0.05
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Discussion
Accumulating evidence associates uPAR expression and func-
tion with obstructive lung disease and airway structural
changes (5, 6, 8, 9, 27). In this study, we aimed to (i) determine
the uPAR cellular expression profile in asthma and control
subject lungs, (ii) further define the association between
scuPAR levels and asthma diagnosis and (iii) investigate corre-
lation between uPAR levels in the airways/circulation and
asthma clinical features. We identified lung tissue uPAR
expression in bronchial epithelial cells, airway smooth muscle
cells and inflammatory cells in the lamina propria and demon-
strate coordinated expression across these locations. Serum
scuPAR was reproducibly elevated in multiple asthma cohorts.
Importantly, we provide the first evidence that serum scuPAR
is elevated in a more severe and in nonatopic subphenotypes of
asthma. These data therefore not only confirm the relationship
between the circulating uPAR and asthma, but provide novel
data identifying a relationship between asthma and expression
in multiple airway cell types. Critically, we highlight the poten-
tial importance of circulating scuPAR, suggesting that this
molecule acts independently to the membrane-bound form and
identified a new asthma phenotype ‘scuPAR high’ that is
severe and nonatopic.
PLAUR is a known asthma susceptibility gene, with
intragene polymorphisms linked to asthma diagnosis, base-
line lung function and lung function decline and serum scu-
PAR levels (7). At the protein level, elevated uPAR has
been identified in post-mortem status asthmaticus lungs (27),
in the asthmatic bronchial epithelium and serum (8, 13). In
the current study, we extend our published findings by
localizing uPAR expression in bronchial tissue and identify-
ing elevated expression in multiple structural cells in
patients with asthma. Association and correlation analyses
confirmed coordinated uPAR expression in lung structural
and inflammatory cells. This suggests a complex relation-
ship between different bronchial structural cells and uPAR
expression, where it has been suggested that uPAR is
involved in a number of airway remodelling linked pro-
cesses, for example wound repair and epithelial proliferation
(8, 13). These data suggest that there may be potential
genetic predisposition in carriers of specific PLAUR geno-
types, to produce elevated levels of uPAR in multiple cell
types and organs; an issue we were unable to address due
to lack of patient numbers and matched biopsies/serum and
genetic information. In support of this concept, a recent
expression quantitative trait loci study of peripheral blood
cells identified that several of the asthma-associated
PLAUR single nucleotide polymorphisms (SNPs) originally
identified (7) were also determinants of uPAR mRNA levels
in blood cells (28).
Based on studies identifying association between serum
scuPAR levels and asthma diagnosis (13) and on genetic
studies linking serum scuPAR to lung function SNPs (7), we
next set out to identify whether scuPAR levels were related
to asthma clinical phenotypes. In the biopsy study, we did
not identify a significant association between uPAR immuno-
histochemical staining and any of the clinical features of
asthma tested including lung function and atopy. Interest-
ingly, a COPD study observed a significant association
between small airway epithelial uPAR levels using immuno-
histochemistry and forced expiratory flow 25–75% (FEF25–75),
suggesting the anatomical location and/or the specific spirome-
try measure may be key (5). Similarly, our lack of association
may be driven by the number of patients in our analyses and
the lack of resolution of IHC to distinguish uPAR isoforms
such as scuPAR which is clearly of significance in the
circulation.
In the serum analyses, we confirmed previous observations
that serum scuPAR is elevated in asthma. This study has
now replicated that scuPAR is also associated with the
asthma phenotype and therefore may also have a defining
and modulatory role in asthma. Although serum scuPAR is
elevated in asthma, the large degree of intersubject variability
suggests that uPAR would not be useful as a marker of
asthma per se. This expression distribution is likely due to
asthma heterogeneity, that is uPAR is not an important
determinant in all types of asthma. Therefore, we set out to
determine whether serum scuPAR is elevated, and by infer-
ence involved in, a specific subset of patients with asthma.
Asthma is a heterogeneous obstructive lung disease (1) com-
prised of different disease subsets (20) which have markedly
different presenting symptoms and degrees of severity, some
of which may have greater association with circulating scu-
PAR. Therefore, we hypothesized that there may be a ‘uPAR
driven’ subset of patients with asthma. Indeed, circulating
scuPAR elevations in the UK cohort appear to be driven by
the severe disease (BTS/SIGN ≥ 3), with no elevation identi-
fied in mild–moderate asthma. Severe asthma defined using
BTS/SIGN is based on asthma symptoms, and the patients
have frequent severe and serious exacerbations despite taking
multiple asthma medications, that is asthma control (29). We
propose that the asthma phenotype identified by elevated
serum scuPAR is managed to a lesser degree by current med-
ication (BTS severe) and therefore may identify a subset of
asthma where there is a therapeutic need. One potential con-
founder of our analyses is steroid use, with greater use of
steroids being a characteristic of the severe asthma group.
However, we formally tested this and show that inclusion of
steroid use in the regression models did not influence this
association between elevated serum scuPAR and severe
asthma (data not shown). It is important to emphasize that
steroid use as a dichotomous trait was included in the regres-
sion model due to the lack of data available for actual doses
of corticosteroids the patients were taking. This means that
while our data suggest that steroid use does not confound
our statistical models and our interpretation of these data we
cannot completely exclude an effect of corticosteroid use on
uPAR expression.
Although disease severity may partially explain the wide dis-
tribution of serum scuPAR levels in our cohorts, the presence
of a large heterogeneity of data even when separated according
to asthma severity suggests that uPAR levels may be also
affected by other defining features of asthma. To investigate
this, we analysed the effect of atopic status on circulating scu-
PAR levels in the Dutch and UK cohorts, identifying that
© 2016 The Authors. Allergy Published by John Wiley & Sons Ltd
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serum scuPAR levels were elevated in nonatopic vs atopic
asthma. As we report potential association with steroid use,
significant in the Dutch cohort (Table 2A), we confirmed that
no confounding of these findings by steroid use was present by
running the regression model with and without this dichoto-
mous (Yes/No) covariant. Again steroid use did not influence
the statistical models used, and the association between ele-
vated serum scuPAR in nonatopic asthma was retained (data
not shown). It is important to note that the relationship
between steroid use and serum uPAR levels in the Dutch
cohort is inconsistent and was not observed in the UK cohort
meaning that it is likely that this is related to the elevated ster-
oid use in nonatopic patients. Analysis of uPAR expression in
bronchial biopsies did not identify association with atopic sta-
tus, suggesting the relationship is driven by scuPAR which in
the biopsy study could not be distinguished from membrane
forms. Similarly, these data may suggest that inflammatory
cells (as in the blood) are one of the main sources of scuPAR
in asthma. The relationship between, for example sputum scu-
PAR and these parameters would begin to address these differ-
ences; however, matched biopsies and serum samples were not
available.
Nonatopic asthma is generally an adult onset disease, often
with a more severe clinical course (30, 31). Analyses of the
cohorts used in this study stratified into atopic and nonatopic
asthma provide some supporting evidence for this, for exam-
ple reduced FEV1 in nonatopic asthma (Tables S2 and S3).
The association of serum scuPAR to a more severe phenotype
of asthma in the current study, and genetic associations
between PLAUR SNPs and lung function in patients with
asthma (FEV1) (7) and smokers (FEV1 and FEV1/FVC) (32),
led us to determine association between uPAR levels and lung
function parameters. We confirmed serum scuPAR is nega-
tively associated with atopic status and positively correlated
with FEV1/FVC in individual UK and Dutch cohorts and in
the combined analyses, suggesting that the serum component
may be a systemic marker of ongoing changes in the airway.
These data suggest scuPAR as a potential marker of airway
obstruction; however, the positive correlation is potentially
counterintuitive, that is elevated uPAR is associated with
more severe asthma but a higher FEV1/FVC ratio suggesting
it is protective for this marker of airway obstruction. Further
examination of the severe asthma subjects in the UK cohort
who demonstrated elevated serum scuPAR levels shows that
these individuals have a reduced FVC compared to moderate
asthma subjects (Table S3). However, FVC was not associated
with serum scuPAR levels in this cohort (data not shown)
suggesting the association with FEV1/FVC is not driven by
FVC. Also, FEV1/FVC associations were not as reproducible
as the atopy correlation, for example in the quartile analyses,
the association between FEV1/FVC and uPAR serum levels
was not present in the UK cohort questioning this finding.
While we have focussed on the role of uPAR in asthma, it
is important to note that this receptor may be of relevance in
a range of human disorders, for example focal segmental
glomerulosclerosis (FSGS) where scuPAR is elevated in dis-
ease (33, 34). Importantly, the study suggests that scuPAR
was an FSGS causative factor via integrin interactions,
including b[3] integrin. Although the veracity of this interac-
tion is currently under discussion (35), there remains evidence
of scuPAR as a direct modulator of disease. Two studies
have identified that scuPAR has functional properties beyond
acting as a decoy for uPA binding including mediating uPAR
signalling as both an agonist and antagonist depending on
the cellular context and promoting migration (12, 36). This
may be of relevance to asthma and further investigations of
the role of scuPAR and integrins in asthma are warranted.
This study has several major strengths, including the exten-
sive analyses of both lung and systemic uPAR levels in large
numbers of asthma and control subjects, to identify differen-
tial expression and the relationship of expression to clinical
features of asthma. The limitations of the study include; that
we did not have matched sputum, biopsy and serum samples
for subjects which would have enhanced the study, as all
measures were not available in all cohorts and that we could
not (technically) distinguish uPAR isoforms in the airways.
Similarly, limited information on the commercial ELISA
used means that we cannot conclude whether both uPA
bound and/or free scuPAR were measured in serum. While
the subjects in our study were recruited and clinically charac-
terized in respiratory centres, it is important to highlight that
we did not collect extensive nonrespiratory comorbidity data
for subjects. Therefore, although unlikely, we cannot exclude
that undiagnosed comorbidities where uPAR may be
involved, may have influenced our data. However, using mul-
tiple cohorts, we have mitigated this risk. It is also useful to
note that the subjects contributing to the current analyses are
enriched for moderate–severe asthma due to the nature of
recruitment from hospital settings, therefore, our subjects
may not entirely be representative of the whole population of
asthma subjects.
In conclusion, this work provides novel insight into the
potential role of the asthma-associated gene, PLAUR in
asthma. Specifically, we identified that uPAR is elevated in a
range of airway structural and inflammatory cells in asthma
and that serum levels of scuPAR are reproducibly elevated in
asthma. Importantly, we report for the first time a ‘serum
uPAR high’ subset of asthma that is predominantly severe
and nonatopic. These data highlight uPAR and in particular,
the soluble form of the receptor as a potentially important
target for further investigation for novel future approaches
to treat asthma, particularly in severe refractory asthma
where new medicines are needed.
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